Compare Dr. Reddys with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PFIZER - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PFIZER DR. REDDYS LAB/
PFIZER
 
P/E (TTM) x 40.0 50.1 79.8% View Chart
P/BV x 5.5 8.3 65.8% View Chart
Dividend Yield % 0.5 0.4 118.2%  

Financials

 DR. REDDYS LAB   PFIZER
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
PFIZER
Mar-19
DR. REDDYS LAB/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,3633,840 87.6%   
Low Rs2,3522,080 113.1%   
Sales per share (Unadj.) Rs1,054.2455.0 231.7%  
Earnings per share (Unadj.) Rs121.993.8 130.0%  
Cash flow per share (Unadj.) Rs190.2109.4 173.9%  
Dividends per share (Unadj.) Rs25.0022.50 111.1%  
Dividend yield (eoy) %0.90.8 115.1%  
Book value per share (Unadj.) Rs938.7658.2 142.6%  
Shares outstanding (eoy) m166.1745.75 363.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.76.5 41.7%   
Avg P/E ratio x23.431.6 74.3%  
P/CF ratio (eoy) x15.027.1 55.5%  
Price / Book Value ratio x3.04.5 67.7%  
Dividend payout %20.524.0 85.5%   
Avg Mkt Cap Rs m474,831135,420 350.6%   
No. of employees `00021.72.6 822.9%   
Total wages/salary Rs m33,8023,238 1,043.8%   
Avg. sales/employee Rs Th8,091.07,911.4 102.3%   
Avg. wages/employee Rs Th1,561.31,230.9 126.8%   
Avg. net profit/employee Rs Th935.81,630.7 57.4%   
INCOME DATA
Net Sales Rs m175,17020,815 841.6%  
Other income Rs m6,2061,674 370.8%   
Total revenues Rs m181,37622,489 806.5%   
Gross profit Rs m24,4215,712 427.5%  
Depreciation Rs m11,348714 1,589.6%   
Interest Rs m98373 1,348.4%   
Profit before tax Rs m18,2966,599 277.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,4032,309 -60.8%   
Profit after tax Rs m20,2604,291 472.2%  
Gross profit margin %13.927.4 50.8%  
Effective tax rate %-7.735.0 -21.9%   
Net profit margin %11.620.6 56.1%  
BALANCE SHEET DATA
Current assets Rs m125,99127,167 463.8%   
Current liabilities Rs m72,1418,917 809.0%   
Net working cap to sales %30.787.7 35.1%  
Current ratio x1.73.0 57.3%  
Inventory Days Days7368 107.8%  
Debtors Days Days10530 348.0%  
Net fixed assets Rs m83,8548,862 946.2%   
Share capital Rs m831458 181.6%   
"Free" reserves Rs m155,15729,656 523.2%   
Net worth Rs m155,98830,113 518.0%   
Long term debt Rs m1,30425 5,216.0%   
Total assets Rs m232,25339,400 589.5%  
Interest coverage x19.691.5 21.4%   
Debt to equity ratio x00 1,006.9%  
Sales to assets ratio x0.80.5 142.8%   
Return on assets %9.111.1 82.6%  
Return on equity %13.014.2 91.2%  
Return on capital %12.622.1 57.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,193428 19,657.5%   
Fx outflow Rs m39,616786 5,037.6%   
Net fx Rs m44,577-358 -12,448.2%   
CASH FLOW
From Operations Rs m29,841978 3,050.9%  
From Investments Rs m-4,923351 -1,401.8%  
From Financial Activity Rs m-25,159-1,099 2,290.3%  
Net Cashflow Rs m-266231 -115.3%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.4 7.5 72.0%  
FIIs % 35.3 4.9 720.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.7 64.6%  
Shareholders   75,885 85,207 89.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE SCIENCES  VENUS REMEDIES  WYETH  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 20, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS